A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

Also called NCT06780410

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 245 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06780410
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06780410. Randomized; double masking; primary purpose treatment. Start 2024-12-20 (actual); primary completion 2025-08-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
Condition
Primary Hyperlipidemia
Intervention (Drug)
Bempedoic Acid Tablet
Intervention (Drug)
Placebo
Lead sponsor
Gan & Lee Pharmaceuticals. (class: industry)

Record details

Record id
cardio:ct-nct06780410
Content hash
74b77e7905bf8ed24a0b0f9bc7766a6c057650dbf4ba40a7b93316cccb9be62a